Dr. Mamounas on Selecting Patients With Breast Cancer for Neoadjuvant Chemotherapy
Eleftherios Mamounas, MD, MPH, medical director, Comprehensive Breast Program, University of Florida Health Cancer Center, discusses the need to select patients for neoadjuvant chemotherapy.
Eleftherios Mamounas, MD, MPH, medical director, Comprehensive Breast Program, University of Florida Health Cancer Center, discusses the need to select patients for neoadjuvant chemotherapy.
There are breast cancer subtypes that respond very well to neoadjuvant chemotherapy: triple-negative, HER2-positive, and ER-positive. Once a pathologic complete response is achieved, the oncologist should be aware of clinical trials that test the concept of less aggressive treatment.
It is important to select patients for neoadjuvant chemotherapy, not only by size or nodal status, but also by subtype.
